Dendritic cells and gut mucosal immune cells (GALT)

Dendritic cells and gut mucosal immune cells represent the integrated cellular network of the gut-associated lymphoid tissue (GALT), which is essential for maintaining intestinal homeostasis (Mowat & Agace, 2014, PMID: 25159613). Dendritic cells (DCs) in the gut mucosa act as specialized sensors that sample antigens from the intestinal lumen and present them to T cells, thereby determining whether the immune system mounts an active response or maintains oral tolerance (Coombes & Powrie, 2008, PMID: 18930295). This complex system also includes intraepithelial lymphocytes, lamina propria mononuclear cells, and IgA-secreting B cells, all working in concert to protect against pathogens while preventing excessive inflammation against commensal bacteria. Dysregulation of these cells is a central driver of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, where a breakdown in tolerance leads to chronic, debilitating inflammation (Neurath, 2014, PMID: 24670451). While this entry refers to a cellular population rather than a single molecular target, it is the site of action for many of the most effective therapies in gastroenterology. Drugs such as vedolizumab target this system by blocking the alpha-4 beta-7 integrin, which prevents the homing of pro-inflammatory lymphocytes to the gut mucosa (Feagan et al., 2013, PMID: 23964721). Other biologics, such as infliximab and ustekinumab, target cytokines like TNF-alpha and IL-12/23 that are produced by or act upon these mucosal immune cells to drive inflammation (Sandborn et al., 2017, PMID: 28244333). Understanding the spatial and functional heterogeneity of these cells remains a critical area of research for developing more precise, gut-selective immunotherapies.

Other names

Gut-associated lymphoid tissueIntestinal mucosal immune systemLamina propria mononuclear cellsMucosal-associated lymphoid tissueMALTIntestinal immune system

Therapeutic modulation involves inhibiting leukocyte trafficking to the gut mucosa via integrin antagonism, neutralizing pro-inflammatory cytokines such as TNF-alpha, IL-12, and IL-23, or modulating sphingosine-1-phosphate (S1P) receptors to sequester lymphocytes in lymph nodes.